Cancer drugmaker TetraLogic Pharma raises $32M Series C
TetraLogic Pharmaceuticals has completed a $32 million Series C fund-raise that the company will use to push its cancer drug through a phase 2a study. The Malvern, Pennsylvania, company’s lead drug candidate, TL32711, is currently in a phase 1 study in patients with solid tumors, according to a statement from TetraLogic. The trial started in […]